Claims for Patent: 11,806,334

Summary for Patent: 11,806,334

Title:	Non-sedating dexmedetomidine treatment regimens
Abstract:	Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Inventor(s):	Vasukumar KAKUMANU, David Christian HANLEY, Frank Yocca, Chetan Dalpatbhai LATHIA, Lavanya Rajachandran, Robert Risinger
Assignee:	Bioxcel Therapeutics Inc
Application Number:	US18/153,870
Patent Claims:	1. A method of treating agitation associated with schizophrenia or bipolar I or II disorder in a human subject comprising: administering an initial dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation to the human; administering a second dose of dexmedetomidine or the pharmaceutically acceptable salt thereof in the oromucosal formulation to the human subject at least two hours after and within 24 hours of the initial dose; and administering a third dose of dexmedetomidine or the pharmaceutically acceptable salt thereof in the oromucosal formulation to the human subject at least two hours after the second dose and within 24 hours of the initial dose; wherein the administration of the dexmedetomidine does not exceed a maximum total daily dosage; wherein the human subject has a severe hepatic impairment and the agitation is severe; and wherein the initial dose is 90 mcg of dexmedetomidine, the second and third doses are each 60 mcg of dexmedetomidine, and the maximum total daily dosage is 210 mcg of dexmedetomidine. 2. The method of claim 1, wherein the agitation is severe as defined by a PEC score of 20 or higher and the hepatic impairment is severe as defined by Child-Pugh Class C. 3. The method of claim 1, wherein the oromucosal formulation further comprises at least one water-soluble polymer. 4. The method of claim 3, wherein the at least one water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, polyethylene oxide (PEO), and mixtures thereof. 5. The method of claim 4, wherein the at least one water-soluble polymer is hydroxypropyl cellulose.